Continuous Glucose Monitoring Microneedle System

Article Title: Continuous Glucose Monitoring System Based On Percutaneous Microneedle Array

Continuous glucose monitoring (CGM) has become an essential tool in diabetes management because it offers real-time data on blood glucose levels, thereby enabling timely interventions to prevent complications. Traditional methods, such as finger-prick tests, are invasive, intermittent, and often painful, limiting their utility in continuous disease management. Chien et al. (2022) study addresses these challenges by developing a wearable continuous glucose monitoring system (CGMS) that utilizes a percutaneous microneedle array for minimally invasive, continuous blood glucose measurement.

The authors aimed to design a CGMS that overcomes the drawbacks of conventional glucose monitoring by integrating a microneedle sensor, a signal conditioning circuit, and a wireless transmission module into a compact, wearable device. The primary research goal was to demonstrate that a microneedle array, with needles only 1 mm in length, could reliably sense glucose concentrations within a physiological range (50-400 mg/dL) without causing significant discomfort or tissue damage (Chien et al., 2022). This objective is critical in biomedical research because continuous, real-time monitoring is imperative for effective diabetes management, reducing complication risks such as cardiovascular disease, neuropathy, and renal failure.

The methodology involved several innovative approaches. Using a specially designed stamping device, a micro-transfer method was employed to deposit glucose oxidase onto the microneedle tips accurately. Cyclic voltammetry was then used to assess the sensor’s performance by measuring the electrical response at an optimal operating voltage of 0.65 V. In the experimental design, the independent variable was the glucose concentration, while the dependent variable was the electrical current generated by the sensor. The results demonstrated a linear relationship between current and glucose concentration, with enzyme deposition variability maintained below 10%. In addition, stability tests in an agar-based skin model and short-term human experiments confirmed that the device maintained consistent performance for up to 7 days and could effectively track postprandial glucose changes (Chien et al., 2022).

This research contributes significantly to the field by providing a viable model for a minimally invasive, wearable CGMS that integrates microscale sensor technology with wireless communication. The study validates the feasibility of using a 1 mm microneedle array for continuous glucose monitoring and sets a foundation for future developments in wearable biosensors. The proposed device can be adapted to detect other analytes, such as lactic acid, uric acid, and cholesterol, broadening its impact in personalized healthcare.